Silver Book Fact

Targeting A-type K+ channels in primary sensory neurons could provide a novel mechanism-based therapy for the treatment of bone cancer pain–one of the most severe types of chronic pain.

Duan K, Xu Q, Zhang X, Zhao Z, et al. Targeting A-Type K+ Channels in Primary Sensory Neurons for Bone Cancer Pain in a Rat Model. Pain. 2012; 153(3): 562-74. http://www.ncbi.nlm.nih.gov/pubmed/22188869

Reference

Title
Targeting A-Type K+ Channels in Primary Sensory Neurons for Bone Cancer Pain in a Rat Model
Publication
Pain
Publication Date
2012
Authors
Duan K, Xu Q, Zhang X, Zhao Z, et al.
Volume & Issue
Volume 153, Issue 3
Pages
562-74
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • In individuals with persistent low back pain, tanezumab, a humanized anti-nerve growth factor antibody, showed clinical and statistical analgesic efficacy that was superior to placebo and naproxen.  
  • Nerve growth factor (NGF) has been found to be a major mediator of inflammatory and neuropathic pain and provides a new therapeutic target.  
  • Pregalbin, an antiepileptic drug, produced around a 32% pain reduction (a significant reduction) at week 16 versus around 20% for placebo, in patients with neuropathic pain due to spinal cord…  
  • Advances in neuroimaging will continue to offer information on the brain’s functioning and how it correlates to the pain experience.  
  • Understanding the role of genetics in pain mechanisms is increasing and the potential now exists to conduct genome-wide screens in model organisms to look for pain-associated genes.